Catherine Jankowski

Dr. Catherine Jankowski

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2014 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
KEKristine M. Erlandson
Kristine M. Erlandson
JSJennifer A. Schrack
Jennifer A. Schrack
CJCatherine Jankowski
Catherine Jankowski
TBTodd T. Brown
Todd T. Brown
TCThomas B. Campbell
Thomas B. Campbell

12 November 2018 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
CJCatherine Jankowski
Catherine Jankowski
PWPamela Wolfe
Pamela Wolfe
SSSarah J. Schmiege
Sarah J. Schmiege
KNK. Sreekumaran Nair
K. Sreekumaran Nair
SKSundeep Khosla
Sundeep Khosla
WKWendy M. Kohrt
Wendy M. Kohrt

8 August 2014 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
CJCatherine Jankowski
Catherine Jankowski
MOMarcia G. Ory
Marcia G. Ory
DFDaniela B. Friedman
Daniela B. Friedman
ADAndrea Dwyer
Andrea Dwyer
SBSarah A. Birken
Sarah A. Birken
BRBetsy Risendal
Betsy Risendal

11 August 2020 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KEKristine M Erlandson
Kristine M Erlandson
MWMelissa P Wilson
Melissa P Wilson
SMSamantha MaWhinney
Samantha MaWhinney
EREric Rapaport
Eric Rapaport
JLJay Liu
Jay Liu
CJCatherine Jankowski
Catherine Jankowski
We investigated whether higher-intensity exercise provided greater decrease in markers of inflammation, and whether responses differed by HIV serostatus. People with HIV (PWH; n = 32) and controls (n = 37) aged 50–75 years completed 12 weeks moderate-intensity exercise, then were randomized to moderate- or high-intensity exercise for 12 additional weeks (n = 27 and 29, respectively). Inflammation biomarkers were measured at 0, 12, 24 weeks. Mixed and multiple regression models were adjusted for baseline inflammation, age, and body mass index. Baseline tumor necrosis factor-α (TNF-α), soluble TNF receptor 2 (sTNFR2), and soluble CD14 (sCD14) were significantly higher among PWH than controls (P < .04). From week 0–12, changes in interleukin-6 (IL-6), TNF-α, and sTNFR1 were not significantly different by HIV serostatus. We found no significant interaction between HIV serostatus/exercise intensity on week 12–24 changes in IL-6, TNF-α, and sTNFR1. Among high-intensity exercisers, PWH and controls had significant increases in sCD14 (P ≤ .003), controls significant increases in IL-10 (P = .01), and PWH nonsignificant decrease in highly sensitive C-reactive protein (P = .07). Other markers were not significantly different by serostatus or intensity. Moderate and high-intensity exercise elicited similar effects on inflammation among PWH and controls, with additional beneficial effects seen among high-intensity exercisers. Increase in sCD14 and attenuated IL-10 increase (PWH only) merit further study. NCT02404792.

1 September 2021 in Geriatric Nursing
Verified
Journal Article
Closed access
DBDawon Baik
Dawon Baik
JSJiyoun Song
Jiyoun Song
ATAluem Tark
Aluem Tark
HCHeather Coats
Heather Coats
NSNadia Shive
Nadia Shive
CJCatherine Jankowski
Catherine Jankowski

Young-Min ParkYoung-Min Park
Young-Min Park
CJCatherine Jankowski
Catherine Jankowski
CSChristine M. Swanson
Christine M. Swanson
KHKerry L. Hildreth
Kerry L. Hildreth
WKWendy M. Kohrt
Wendy M. Kohrt
KMKerrie Moreau
Kerrie Moreau
Although estradiol (E2) has been believed to be the most critical factor in the menopause-associated decrease in bone mineral density (BMD), the role of increasing follicle stimulating hormone (FSH) during menopause is relatively unclear. We determined the extent to which hip and lumbar spine BMD differ among the stages of menopause in healthy women, and whether BMD is associated with FSH and E2 levels. A cross-sectional study of 141 healthy women classified as premenopausal (Pre; 38 ± 6 yrs; mean ± SD, n = 30), early perimenopausal (EPeri; 50 ± 3yrs, n = 31), late perimenopausal (LPeri; 50 ± 4yrs, n = 30), early postmenopausal (EPost; 55 ± 3yrs, n = 24), or late postmenopausal (LPost; 62 ± 4 yrs, n = 26), was conducted. Spine/hip BMD and sex hormones were measured using dual-energy X-ray absorptiometry and enzymatic/colorimetric methods, respectively. Compared to EPeri, spine BMD was lower (p < 0.05) in LPeri, EPost, and LPost and hip BMD was lower (p < 0.05) in EPost and LPost. BMD was inversely associated with FSH (spine: r = −0.341; hip: r = −0.271, p < 0.05) and directly associated with E2 (spine: r = 0.274; hip: r = 0.256, p < 0.05). The menopause-related loss of spine and hip BMD is associated not only with low E2 but also higher FSH. Future studies are essential to delineating the mechanisms by which FSH regulates bone health in aging women.